Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment.

Song HT, Sun XY, Zhang L, Zhao L, Guo ZM, Fan HM, Zhong AF, Niu W, Dai YH, Zhang LY, Shi Z, Liu XP, Lu J.

J Psychiatr Res. 2014 Jul;54:134-40. doi: 10.1016/j.jpsychires.2014.03.008. Epub 2014 Mar 20.

PMID:
24694668
2.

A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.

Sun XY, Zhang J, Niu W, Guo W, Song HT, Li HY, Fan HM, Zhao L, Zhong AF, Dai YH, Guo ZM, Zhang LY, Lu J, Zhang QL.

Am J Med Genet B Neuropsychiatr Genet. 2015 Apr;168B(3):170-8. doi: 10.1002/ajmg.b.32292. Epub 2015 Feb 5.

PMID:
25656957
3.

Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients.

Sun XY, Lu J, Zhang L, Song HT, Zhao L, Fan HM, Zhong AF, Niu W, Guo ZM, Dai YH, Chen C, Ding YF, Zhang LY.

J Clin Neurosci. 2015 Mar;22(3):570-4. doi: 10.1016/j.jocn.2014.08.018. Epub 2014 Dec 6.

PMID:
25487174
4.

Dysregulation of miRNA 181b in the temporal cortex in schizophrenia.

Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I, Cairns MJ.

Hum Mol Genet. 2008 Apr 15;17(8):1156-68. doi: 10.1093/hmg/ddn005. Epub 2008 Jan 9.

5.

Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.

Yang J, Liu H, Wang H, Sun Y.

Pathol Res Pract. 2013 Aug;209(8):490-4. doi: 10.1016/j.prp.2013.04.018. Epub 2013 Jun 6.

PMID:
23827213
6.

MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission.

Liu S, Yuan YB, Guan LL, Wei H, Cheng Z, Han X, Yang L, Pu CC, Yang FD, Lu Z, Deng H, Zhao JP, Yu X.

Chin Med J (Engl). 2013 Jul;126(14):2676-80.

7.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
8.

Aberrant expression of serum miRNAs in schizophrenia.

Shi W, Du J, Qi Y, Liang G, Wang T, Li S, Xie S, Zeshan B, Xiao Z.

J Psychiatr Res. 2012 Feb;46(2):198-204. doi: 10.1016/j.jpsychires.2011.09.010. Epub 2011 Nov 16.

PMID:
22094284
9.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
10.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
11.
12.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M.

J Clin Psychiatry. 2004 Apr;65(4):551-6.

PMID:
15119920
13.

Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.

Liu-Seifert H, Osuntokun OO, Feldman PD.

Compr Psychiatry. 2012 Jan;53(1):107-15. doi: 10.1016/j.comppsych.2010.12.003. Epub 2011 Feb 9.

PMID:
21310400
14.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
15.

Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients.

Yu HC, Wu J, Zhang HX, Zhang GL, Sui J, Tong WW, Zhang XY, Nie LL, Duan JH, Zhang LR, Lv LX.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:23-9. doi: 10.1016/j.pnpbp.2015.05.007. Epub 2015 May 16.

PMID:
25985888
16.

A preliminary analysis of microRNA-21 expression alteration after antipsychotic treatment in patients with schizophrenia.

Chen SD, Sun XY, Niu W, Kong LM, He MJ, Fan HM, Li WS, Zhong AF, Zhang LY, Lu J.

Psychiatry Res. 2016 Jul 1;244:324-332. doi: 10.1016/j.psychres.2016.04.087. [Epub ahead of print]

PMID:
27512922
17.

Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.

Simpson GM, O'Gorman CJ, Loebel A, Yang R.

CNS Spectr. 2008 Oct;13(10):898-905.

PMID:
18955945
18.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
19.

Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.

Konarzewska B, Waszkiewicz N, Galińska B, Szulc A.

Neuro Endocrinol Lett. 2013;34(4):322-8.

PMID:
23803867
20.
Items per page

Supplemental Content

Write to the Help Desk